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ABSTRACT 
 
Effective therapy of complex diseases requires control of highly non-linear 
complex networks that remain incompletely characterized. In particular, drug 
intervention can be seen as control of signaling in cellular networks. Identification 
of control parameters presents an extreme challenge due to the combinatorial 
explosion of control possibilities in combination therapy and to the incomplete 
knowledge of the systems biology of cells.  
In this review paper we describe the main current and proposed 
approaches to the design of combinatorial therapies, including the empirical 
methods used now by clinicians and alternative approaches suggested recently 
by several authors. New approaches for designing combinations arising from 
systems biology are described. We discuss in special detail the design of 
algorithms that identify optimal control parameters in cellular networks based on 
a quantitative characterization of control landscapes, maximizing utilization of 
incomplete knowledge of the state and structure of intracellular networks. The 
use of new technology for high-throughput measurements is key to these new 
approaches to combination therapy and essential for the characterization of 
control landscapes and implementation of the algorithms.  
Combinatorial optimization in medical therapy is also compared with the 
combinatorial optimization of engineering and materials science and similarities 
and differences are delineated. 
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1. INTRODUCTION 
Combinatorial Biological Control is a growing field that is benefiting from 
advances in systems biology, targeted therapeutics, and high-throughput 
biological measurement technologies as well as from new and established 
approaches from mathematics, physics and engineering. 
The study of Combinatorial Therapies is the fastest expanding sub-
discipline within this field, though therapeutic applications are not the only uses of 
the new principles and methods that are being discovered. Combinatorial 
approaches can also be used to optimize the survival and differentiation of cells 
in vitro, in synthetic genomics, to delay aging, and to improve physiological 
performance. Additionally, work in this field can help elucidate the strategies 
nature uses for combinatorial control and optimization at different scales, from 
evolution to organismal function. While until recently combinatorial therapies 
were based on largely empirical methods, new insights are arising from systems 
biology and from the integration of several biological and non-biological 
disciplines and are providing the prospect of more rational approaches to the 
therapy of complex diseases. 
In this review, we describe the state of the art of combinatorial 
optimization of medical therapy, starting with relevant contributions from systems 
biology. We then compare it with more established techniques of systematic 
optimization in engineering and material sciences.  
 
2. BIOLOGICAL ROBUSTNESS 
The problem of controlling a biological system is complicated by the 
presence of active mechanisms to maintain function (whether homeostatic or 
dynamic, e.g., oscillations, differentiation) under the influence of environmental 
perturbations. This robustness is a desirable property of many complex systems 
that has been studied extensively for engineered systems and more recently 
applied to biological systems. Kitano [1] provided a mathematical framework to 
define and understand biological robustness that takes into account the 
maintenance of function for all possible perturbations, the probability of 
occurrence for each perturbation, and the limited resources available. Kitano also 
suggested that robustness is conserved for similar biological systems, meaning 
that under resource constraints there is some tradeoff in improving robustness to 
certain perturbations while becoming increasingly fragile to others [1]. Stelling et. 
al. [2] agreed with this conjecture, and a similar result was also a consequence of 
the theory of Highly Optimized Tolerance (HOT) for complex designed systems 
[3, 4]. The HOT theory assumes that the final products of biological evolution 
have similar robustness properties to designed systems in engineering. 
It has recently been pointed out that biological networks, in order to 
optimize the crucial tradeoff between robustness and sensitivity [5] must have 
maximal mutual information exchange between nodes [6]. This su ggests that 
natural selection has acted in cells, neural systems, and other tissues so as to 
maximize the information transfer between signaling and receiving nodes across 
their networks.  
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Following this information theory approach, Kitano [1] also suggested the 
concept of controlling biological systems by applying the general principle of 
spread spectrum communication [7], in which selectivity and tolerance to noise is 
achieved by spreading the signal through many channels or nodes in a network. 
In the case of drug design, this approach suggests that efficient and highly-
selective therapies could be obtained combining a large number of low-dose 
compounds. This is supported by numerical studies showing that multiple weak 
hits can affect a regulatory network more efficiently than a complete inactivation 
of selected nodes [8]. 
The consequence of biological robustness in terms of our attempt to 
control these systems is that specific targets for robustness and fragility must be 
understood in order to circumvent the intrinsic tendency of biological systems to 
maintain function (whether in the normal or diseased state) under external 
influences [1]. Theoretical and applied examples of distributed robustness and 
redundancy in the face of cascading failure support the idea that biological 
networks are robust to single interventions [9-12]. Therefore, multiple drugs will 
be needed to address robust disease states.  
 
 
3. THE PROBLEM OF COMBINATION THERAPY 
It is indeed becoming increasingly evident to the clinician treating a 
complex disease or to the scientist studying a complex biological network that 
accurate control is more likely to be achieved by using multiple interventions. 
Since therapeutic molecules are increasing in specificity (as in the case of 
targeted drugs), and since our knowledge of the complexity of biological 
networks is advancing, it is becoming more feasible to consider drugs not as 
remedies for specific disorders but rather as a kit of molecular tools that can be 
combined for specific therapeutic purposes. Additionally, as we do when 
evaluating the health effects of natural products (for example, red wine or green 
tea), it may be acceptable to consider a novel large combination of compounds 
as a whole rather than studying all its components separately. 
Because drug effects are dose-dependent, several doses need to be 
studied and, when therapeutic interventions on multiple targets are necessary, 
the number of possible combinations rises very quickly (this problem is often 
referred to as combinatorial explosion). For example, if we were to study all 
combinations of 6 out of 100 compounds (including partial combinations 
containing only some of these compounds) at 3 different doses we would have  
 
Σ6j=1 Binomial(100,j)*3j = 8.9*1011  
 
possibilities. This example suggests that the problem will require a qualitatively 
new approach rather than more efficient screening technology alone. Many 
cancer chemotherapy regimens are composed of 6 or more drugs from a pool of 
more than 100 clinically used anticancer compounds.  
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The following quotation from the final chapter of a recent textbook on the 
Biology of Cancer [13] by Robert Weinberg illustrates the growing awareness of 
this problem and of new opportunities for its solution: 
 
“Traditionally, new drugs have been evaluated as single agents during pre-clinical 
development and Phase I clinical trials. This practice contrasts with the growing belief of 
cancer researchers that most monotherapies are unlikely to yield curative treatments and 
that, with rare exceptions, truly successful clinical outcomes will depend on the use of 
combinations of anti-cancer drugs.  … At present, the choice of drugs to be used singly or 
in combinations is inspired by biological intuition or poorly performed guesses. 
Increasingly over the coming decade, strategies for organizing multi-drug treatment 
protocols will be influenced by our rapidly evolving understanding of the design of the 
signaling circuitry within human cells and by molecular diagnostics that tell us how 
certain signaling pathways have been perturbed in some tumors and not in others.” 
 
A similar view on the limitations of the traditional approach to drug 
combination has been offered by Sridar Ramaswamy in a recent Commentary in 
The New England Journal of Medicine [14]. Other reviews stressing the need for 
a more systematic approach to combination therapy have been published by 
Dancey and Chen [15], Hopkins [16] and Zimmerman et. al. [17]. A recent 
editorial [18], commenting on the disappointing results of a clinical trial of 
combination therapy for colorectal cancer [19], suggested that combining the new 
targeted therapies might be even more challenging than combining cytotoxic 
chemotherapies, because of subtle interactions in intracellular signaling. 
 
4. COMBINATORIAL OPTIMIZATION IN MEDICAL THERAPY  
 In the following sections we describe the main classes of strategies for 
designing drug combinations (or closely related approaches) presented in the 
literature. 
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Class A  - Empirical method (not systematic) 
 
 
 
Figure 1: The empirical method. This approach is non-systematic, instead designing 
combinations based on the clinical experience of doctors, knowledge of biological 
mechanisms, and practical constraints in the design of clinical trials. 
 
In this class we include the traditional approaches. It is important to stress 
that by empirical [15, 20] we mean that the approach is not systematic. We do 
not mean that empirical approaches are non-scientific: on the contrary, many 
clinical trials of drug combinations are very rigorous and clearly useful [18, 19]. A 
common assumption in this class is that only drugs that are effective individually 
should be used as part of a drug combination [21]. This assumption might be 
related to FDA requirements, which however now seem to be evolving [13]. 
Because clinical trials are very expensive and many are sponsored by drug 
companies, it has been pointed out that commercial factors play a role in the 
choice of which combinations are tested [22]. The FDA regulates which individual 
drugs can be prescribed but individual physicians are free to use their clinical 
judgment when prescribing them in combination. We do not assume that a 
systematic approach would be necessarily be superior, but randomized, double 
blind, prospective trials could compare the efficacy of specific systematic 
approaches with physician choices. Improving the evaluation of the efficacy of 
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medical therapy is one of the measures suggested for reducing inefficiencies in 
health care expenditures [23]. 
 
 
 
 
Class B – Brute force (exhaustive enumeration) 
 
 
 
Figure 2: The brute force approach. “Brute force” is a term meaning exhaustive testing of all 
possible combinations. High-throughput screening technology allows the testing of pairs 
of drugs over a range of doses, but combinatorial explosion usually prevents exhaustive 
measurement of combinations of more than 2 drugs except when exploring combinations 
from very limited sets of compounds. 
  
 
This approach has been called “brute force” to indicate that all 
combinations up to a certain size are tested [17, 24]. Because of the mentioned 
rapid combinatorial explosion this means that only combinations of a smalI size 
can be studied. A “brute force algorithm” is a technical definition for an algorithm 
that performs an exhaustive search. It does however require a considerable 
amount of judgment to decide which set of drugs to test and which biological 
assay to use.  
Most studies in the literature only study pairs of drugs, and it would be 
very difficult to extend this approach to larger combinations unless the set of 
candidate compounds to be used is small. Greco [25] reviews the traditional 
literature on drug combinations and drug synergy, which was mainly developed 
to study interactions of two drugs. Te Dorsthorst [26] presents a recent 
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application of this approach applied to the study of antifungal agents. A more 
systematic approach is suggested by Borisy et. al. [27] using high-throughput 
screening in several different biological systems and measuring hundreds of 
thousands of pair-wise drug interactions. 
The main idea underlying this approach is that unexpected therapeutic 
activities, not predictable from single drug studies, might manifest themselves 
when multiple drugs are used, and this seems to be the case, see e.g., [18, 19, 
27]. 
 
 
Class C – Statistical association 
 
 
 
Figure 3: Statistical association models. This approach attempts to design combinations 
based on the desired phenotype and linear combinations of input/output relationships of 
single drugs. 
 
Statistical models can be built based on correlations between drugs and 
phenotype outputs. These models do not rely on an explicit characterization of 
the biological networks but treat the system as a black box. By predicting 
phenotype outputs in response to new sets of drug inputs and assuming simple, 
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usually linear, relationships, these statistical models can aid in the design of drug 
combinations. 
Lamb et. al. [28] compiled a database of gene expression profiles in 
response to single agents. The “Connectivity Map” allows new samples to be 
matched to gene expression patterns so that the best set of single drugs can be 
found. Although the database can be used to connect related small molecules, 
using data from a limited number of cell lines and compounds, no attempt has 
been made to use the resource to design new combinations. Janes et. al. [29] 
used partial least-squares regression to develop a statistical model linking a 
signature of apoptosis markers to an array of activity metrics in 19 signaling 
proteins, when activated by different combinations of cytokines. Their method 
demonstrated the ability of the statistical model to determine a canonical basis 
set for combinatorial control of the apoptosis response, using cytokines as inputs. 
Taking advantage of the large-scale screen of drug responsiveness in the 
NCI-60 panel of cancer cell lines, as well as microarray data for each cell line, 
Potti et. al. [30] derived gene expression signatures to classify cell lines on the 
basis of sensitivity to various chemotherapeutics. These expression signatures 
could predict drug sensitivity in cell lines as well as in patients in clinical trials. 
When individual expression signatures were combined to produce a 
chemosensitivity signature for a specific drug combination (TFAC – paclitaxel, 5-
FU, adriamycin, and cyclophosphamide), these genes produced a statistically 
significant distinction between responders and non-responders in a retrospective 
analysis of clinical trials for combination efficacy [30]. 
It is very hard for pure statistical correlations to capture the non-linearity, 
complexity and variability of biological networks, but mechanistic network models  
are still incomplete and the parameters are often not well known, making the 
statistical approach a useful tool especially when dealing with large omic 
datasets. 
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Class D- Explicit model-based methods  
 
 
Figure 4: Model-based approach to designing combinations. Explicit models of biochemical 
interactions, usually fitted to measured biological data (including genome-wide or “omic” 
data such as microarrays), are used to predict optimal combinations via simulation. 
 
In this class, biological measurements (either obtained by the authors or 
derived from the literature) are used to build explicit models of the target 
biological network for the optimization of drug combinations using simulations. 
Any control system implicitly assumes a model of the system being controlled 
[31], but in an explicit model there is a direct correspondence between the 
elements of the model and reality. 
Araujo et. al. [32] used a medium-size system of ordinary differential 
equations to model a handful of combinations on the EGFR network and found 
synergistic interventions. Calzolari et. al. [33] developed a model of the apoptosis 
network and identified general strategies and potential targets for combined drug 
interventions to obtain selective cell death. Yang et. al. [34] modeled the 
arachidonic acid metabolic network, related to inflammation, with a 2-step 
simulated annealing approach to optimize (1) drug candidates and (2) levels of 
intervention for multiple targets. Hua and Palsson [35] is one example of a large 
body of work on control and analysis of metabolic networks using genome-scale 
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constraint based approaches. They predict and design gene knockouts to 
optimize metabolite production. 
Tvieto and Lines [36] took advantage of well established mechanistic 
models of cardiac myocyte electrophysiology [37] to perform an in silico search 
for combinations of ion-channel targets that minimized the effects of ischemia on 
action potential morphology [36]. They confirmed that the optimal combination 
therapy reduced the pro-arrhythmic consequences of regional ischemia in a 
spatially coupled model of myocardial tissue. The method made use of the well 
known Nelder-Mead optimization method [38] to find an optimal "drug vector" 
describing the fractional inhibition or agonism of six channel conductances. The 
optimization minimized a distance function that measured time integrals of 
squared differences in membrane potentials and current densities between 
treated and untreated normal cells, and between treated ischemic cells and 
normal cells. 
Some authors have the opposite but related aim of using drug 
combinations to build network models. The focus is on system analysis rather 
than on system control. Lehar et. al. [39] used response surfaces of pair-wise 
combinations to predict network motifs surrounding the drug targets. The shape 
of a simulated dose response surface can distinguish parallel and serial 
conformations, branching, feedback, etc. in a generic computational abstraction 
of a metabolic network. They then tested the method on the well-known sterol 
metabolism pathway in yeast, noting that the response surfaces of drug pairs 
correctly predicted the topology of the pathway. The method can be generalized 
to higher-order combinations as well. 
Nelander et. al. [40] built a nonlinear multiple-input, multiple-output 
network model using experimentally measured drug pair inputs and phospho-
protein outputs in MCF7 breast cancer cells. They applied Monte Carlo methods 
to optimize the choice of network connectivity, and a gradient descent technique 
to optimize parameters and interaction weights. As opposed to the response 
surface method of Lehar et. al. [39], this method produces globally parameterized 
computational models ready for simulations.  
This class is likely to be an essential component of a successful approach 
to the optimization of drug combinations but we should not forget that we do not 
have the luxury of having a specific drug to modulate each node of a network. 
Targeted therapies are only available for a minority of proteins, and they normally 
have off-target effects, some of which are not known.  
It is also possible to envisage that explicit network models and statistical 
associations could be combined, as it has been done in other fields of systems 
biology, for example in the use of microarrays and protein interaction networks 
for tumor classification [41]. The statistical approach could either be used to 
define the parameters of the model or directly to suggest combinations. We are 
not dedicating a separate section or figure to this class (which can be called 
class E) because we have not found direct examples in the field of combinatorial 
therapy. It is too early to exclude that these types of approaches might emerge, 
but if class E will remain empty or scarcely populated it might be useful to 
consider the reasons. 
12 
 
 
Class F- Model free biological search algorithm 
 
 
 
Figure 5: Biological search algorithm. In this model-free approach to combination design, 
drugs are iteratively combined and measured, in effect searching through the vast space 
of possibilities.  
 
This class describes biological search algorithms, where the search is not 
conducted in silico but directly using biological measurements from in vitro or in 
vivo systems. These methods can be stochastic, for example using Monte Carlo 
or evolutionary algorithms, or non-stochastic. 
Wong et. al. [42] developed a closed-loop control algorithm, using a 
microfluidic platform to implement an iterative stochastic search (Gur Game 
algorithm) for optimal drug combinations. The algorithm efficiently discovered 
potent combinations for inhibiting virus infection of fibroblasts, and was able to 
regulate NFκB levels by discovering optimal cytokine levels. Sun et. al. [43] 
extend this work by using the Gur Game algorithm followed by the Differential 
Evolution algorithm, a type of genetic algorithm that can be used for parallel 
search. 
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Figure 6: Using the biological search algorithm (“Stack Sequential – Top Down” or SS-
TD) to optimize combinations for cancer cell selectivity.  The colors indicate the 
selectivity of the drug interventions and the aim is to find treatments with high selectivity 
for one of the cell lines. This desired selectivity is shown as dark blue. The red shades 
are partially selective for the other cell line. Iterations of the algorithm apply different sizes 
of combinations, starting with individual drugs. A statistically significant enrichment of the 
desired selective combinations (dark blue) is shown. Adapted from [44]. 
 
 
Calzolari et. al. [44] used non-stochastic algorithms derived from one used 
in digital decoding, the stack sequential algorithm, to perform biological searches 
for drug combinations, both in vivo (using fruit flies) and in vitro (using cell lines – 
see Figure 6). This approach is a first example of application of information 
theory concepts and techniques to the control of biological systems.   
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Figure 7: Diagram of the iterative search framework. At each iteration, a high-throughput 
assay measures cellular (or organism) phenotype in response to a drug combination, 
which is fed into the algorithm. The algorithm then generates new candidate 
combinations to test based on the previous results. Conceptually, this is equivalent to a 
search through the phenotype landscape in the space of possible drugs and doses. 
 
 
Further progress within this class would benefit from the availability of a 
corpus of fully factorial (exhaustive) drug combination datasets that could be 
used to compare algorithms and to develop new ones. A detailed statistical 
analysis of these fully factorial datasets could help in testing and evaluating the 
efficiency of different optimal drug combination search strategies. This type of 
analysis can be carried out by characterizing the general properties of the control 
landscape of a given biological system (Figure 7).  
 The notion of landscape represents a very useful concept, commonly used 
in the analysis of many complex systems encountered in physics, biology, 
computer science, and engineering [45]. The analysis of the general properties of 
a landscape is of interest in the context of optimization problems since it provides 
hints on the type of optimization algorithms that are more likely to succeed 
(Figure 8). For instance, in the control of molecular systems by laser pulses, 
different choices of parameters lead often to equivalent outcomes. This is 
reflected in the fact that in these systems optimal solutions lie in high-
dimensional continuous surfaces of the control landscape [46]. In such types of 
landscapes, which can be visualized as having plateau regions in the control 
space, an efficient optimization algorithm needs to “jump” between the different 
plateaux. This can be better achieved using stochastic algorithms, for example 
genetic algorithms (see Section 5: Combinatorial optimization in engineering). 
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Figure 8: Scheme of different types of landscapes. The structure of the control landscape can 
inform the choice of the search strategy. Left: Rugged, found e.g. in spin glasses as a 
result of competition between ferromagnetic and anti-ferromagnetic interactions. Center: 
Funnel, found e.g. in protein folding fitness landscapes. Right: Robust, found e.g. in 
quantum control problems in which often control parameters give perfect control or no 
control at all.  
 
 
 
Class G- Model plus biological search algorithm (integration of C, D and F) 
 
 
 
Figure 9: Modeling approaches integrated with experimental search. A more systematic 
approach could integrate information from statistical and explicit models. Model-based 
predictions of effective perturbations can be combined with closed-loop iterative 
experimental search to refine the drug combination. 
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Calzolari et. al. [44] discussed the motivation for this class and describe in 
detail algorithms that can be used to integrate biological search with statistical 
association and explicit model approaches. What characterizes this class is the 
combination of the experimental search of class F with in silico models (class C, 
class D or both).  
The algorithms described by Calzolari et. al. [44] (see Figure 10 of that 
paper) can include the results of in silico models within the ranking used to guide 
the steps of the experimental search. They therefore do not simply combine the 
outputs of separate approaches but integrate them fully. 
This class of strategies for combinatorial therapy could also utilize the vast 
amounts of genomic data originating from personalized medicine efforts. 
Sequencing individual genomes at an affordable cost might soon be possible.   
Personalized combinatorial therapy might therefore be based both on the 
individual genome (and other omic data) and on an experimental search (as in 
class F) using the individual’s own cells. 
As for class F, it would be desirable to obtain a corpus of fully factorial 
(exhaustive) drug combination datasets and corresponding omic data that could 
be used to develop strategies of this type.  
 
 
5. COMBINATORIAL OPTIMIZATION IN ENGINEERING 
The solution to many engineering problems incorporates ideas that can be 
traced back to combinatorial research, where the individual elements to be 
combined change greatly among different applications. Examples include the 
selection of waiting time combinations at airport gates in order to minimize air 
traffic congestion [47], the combined tuning of the parameters of several 
controllers (each one contributing to a desired objective) in supply chain 
management [48], the optimization of engine parameters such as intake, 
exhaust, and spark timings according to operating conditions to improve fuel 
consumption [49], or the adjustment of ion-intensity model parameters in 
magnetospheric image processing [50]. 
Exhaustive enumeration (as in class B) is a trivial but very general 
problem-solving technique in combinatorial optimization that consists of 
systematically enumerating all possible configurations in searching for the 
optimal solution. Because of combinatorial explosion the method is only suitable 
for low-dimensional problems. 
 In computational science and engineering, when a reliable model of the 
problem is available (as in class D), the search for optimal combinations of the 
individual components can be carried out with a variety of optimization methods. 
For example, in convex optimization, a known and convex objective function is to 
be optimized over a convex domain. For convex functions, any local minimum is 
also global. Also, the set of all minima is convex. Finally, if the function is strictly 
convex, then there exists at most one minimum. Powerful methods exist to obtain 
global optimizers in this case. These include interior-point methods, subgradient 
methods, elliposoid methods, and duality. Numerous problems that are not 
convex in their original variables can be transformed into convex form after a 
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suitable change of variables, and are therefore amenable to convex optimization 
techniques [51].   
 In stochastic optimization, good models are often not available, or we do 
not have an analytical expression for the objective function that we wish to 
optimize, or the evaluation of this function is costly or only possible through 
experimentation.  In such cases, methods that do not depend on direct gradient 
information or exact measurements become very useful.  Recently, there has 
been an increasing interest in recursive stochastic optimization methods that are 
based on noisy measurements of the objective function to be optimized, rather 
than on direct measurements of its gradient. These algorithms have the 
advantage of not requiring detailed modeling information describing the 
relationship between the parameters to be optimized and the objective function. 
The establishment of rigorous theoretical guarantees on the convergence 
properties of these algorithms is a subject of current research. Overall, gradient-
free stochastic optimization methods have similar convergence properties as 
gradient-based stochastic algorithms. Although the theoretical asymptotic 
characterization states that gradient-free methods typically require a larger 
number of iterations until convergence, they offer great computational savings in 
the number of function evaluations required step and are more robust to noise 
and model uncertainty. A method that seems particularly well suited for 
combination therapy (in class F) is the "simultaneous perturbation stochastic 
approximation (SPSA)" [52]. The SPSA is based on approximating the gradient 
of the objective function using only two (possibly noisy) measurements, 
regardless of the dimension of the optimization problem. This feature allows for a 
significant decrease in the implementation cost in high-dimensional optimization 
problems. The applications of SPSA include model-free control [53], simulation-
based optimization, and image processing. The global convergence properties of 
SPSA have been recently studied in [54].   
 Strategies inspired by evolution are potentially useful in class F. Evolution 
strategies use mechanisms inspired by biological evolution such as mutations, 
crossovers, and selection. Examples include genetic algorithms, particle swarm 
optimization, and ant colony optimization. In an evolutionary algorithm, candidate 
solutions play the role of individuals in a population. At each iteration, the fitness 
of every individual is evaluated.  Multiple individuals are stochastically selected 
from the current population based on their fitness and modified according to the 
biological mechanisms mentioned above to form a new population. The new 
population is then used in the next iteration of the algorithm. The implementation 
of these algorithms therefore requires two basic elements: a representation of the 
solution domain and a fitness function to evaluate potential solutions.  The fitness 
function is determined by the objective function of the optimization problem. In 
general, no convergence guarantees are available for these methods. 
 Simulated annealing simulates the cooling process of a physical system. 
Starting at a very high temperature, a series of temperature decreases is 
performed. At each temperature step, the state of the system evolves according 
to some transition probabilities chosen according to the physical problem. The 
idea is that, at high temperatures, movements that result in temporary increases 
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of the objective function are more likely to happen, while as the temperature 
approaches zero, disappear in favor of a steepest descent motion.  If the cooling 
of the procedure is performed slowly enough, then, with high probability, the 
global optimum of the optimization problem is achieved [55]. 
Search algorithms potentially belonging to class F are typically used in 
engineering within a model of the system, rather than experimentally in the real 
system. Research in materials is a distinct exception to this observation, as we 
discuss below. 
An analogy with class G can be found in robotics and artificial intelligence. 
Explicit models of reality are not sufficient for robots to manage a complex 
environment [56]. An alternative approach that started from simpler stimulus-
response algorithms was more successful and was later integrated with the older 
models in hybrid architectures [56]. This process is similar to the evolution of the 
nervous system which is based on stimulus-response mechanisms of increasing 
complexity in lower invertebrates, integrated (but not replaced) by 
representations of reality within the brain of higher organisms. Compare Figure 9 
for class G with Figure 1 of [57].  
 
 
6. COMBINATORIAL OPTIMIZATION IN MATERIALS RESEARCH 
Modern combinatorial materials research is considered to have 
commenced in 1995 [58] leading to a rapidly expanding literature that according 
to a recent estimate is over 10,000 publications [59]. Experimental methods have 
been developed for combinatorial screening of a wide range materials systems 
[58-60], including: catalysts [59]; thin polymer films [59, 61]; ternary inorganic 
compounds [58]; and polymers for biomedical applications [62].  High throughput 
cell based assays with over 1000 units [63] have been used to assess the effect 
of polymers on cellular response [62-64]. There is a strong industrial impetus for 
these developments and national centers of excellence in combinatorial materials 
research, including the NIST center for combinatorial methods (NCMC), and the 
Combinatorial Sciences and Materials Informatics Collaboratory (CoSMIC) at 
Iowa State, have been established. Very large combinatorial arrays have been 
fabricated, particularly in the area of inorganic films where screens containing 
thousands of different stoichiometries have been reported [58].  
Most combinatorial materials experiments operate in a cycle where the 
early experiments generate interesting regions of parameter space, while later 
experiments focus more closely on leads generated in previous cycles [59, 60, 
65, 66]. Lead identification has also been enhanced by using statistical indicators 
based on prior knowledge and by incorporating theoretical insights. Use of prior 
knowledge through quantitative structure-property (QSPR), structure-activity 
(QSAR) or composition-activity (QCAR) relations profits from machine learning 
procedures and through use of artificial neural nets [59].  Optimization methods, 
such as Monte Carlo and genetic algorithms, have been used to assist in the 
choice of promising leads and hybrid methods incorporating prior knowledge 
through machine learning and optimization methods are emerging (see Figure 8 
of ref. [59]). The methodologies used in combinatorial materials research have a 
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great deal in common with those used in searches for drug combinations, and 
the cross-fertilization of these areas is promising.  
In some cases theoretical models are sufficiently accurate that a purely 
computational approach to combinatorial materials design is feasible, as 
illustrated by use of density functional or quantum chemistry methods with 
optimization methods to predict new compounds or chemicals with desired 
properties; for example semiconductors with desired band gaps [67], new stable 
alloys consisting of four elements [68], and molecules with optimized properties 
[69]. De novo computational methods for designing individual drugs are also 
developing rapidly [70]. 
Approaches to combinatorial materials research can be classified 
according to the categories used in this review, ranging from more empirical and 
brute force experimental approaches [58, 62] (as in classes A and B), to the use 
of statistical association methods [66] (as in class C), methods based on explicit 
models [67-69] (as in class D), the use of search algorithms based on the 
experimental data [59] and often using data mining methods [59, 60] (as in class 
F).  Recent approaches strive toward combining all these methods in meaningful 
ways [59, 71] (as in classes E,G). 
 
 
7. FUTURE DEVELOPMENTS 
As described in Steil et. al. [72] and in Weinzimer et. al. [73], it is possible 
to dynamically control in vivo, with real time feedback, the effect in humans of a 
single drug (in this case insulin). In the engineering literature the word control is 
usually used in this dynamical sense. The previously cited biological references 
have the more limited aim of optimizing drug combinations to be applied at a 
single time point. This class of feedback controlled in vivo algorithms, which 
would most likely include all previously described approaches and probably 
others, seems to us one of the possible future developments of combinatorial 
biological control using drugs. The success with a single drug shows that this 
expectation is not unrealistic. 
The choice of a clinically relevant biological output, to be optimized in the 
cells or in the organisms, is also a difficult problem that is shared by scientists 
working on individual drugs. Not only can we expect increased knowledge from 
omic data to help translate from experimental systems to patients, but the 
emergence of adaptive designs in clinical trials might also allow these to be 
structured as search algorithms [74]. 
A more systematic approach is also needed for choosing the subset of 
drugs within which to search for optimal combinations. Systems biology can 
probably assist this choice, especially for the increasing number of targeted 
therapies available [75, 76], where a more precise correspondence between drug 
and biological target can be established. 
We have described many possible algorithms for efficiently searching the 
space of possible drug combinations, and this supports the need for a corpus of 
fully factorial drug combination datasets (landscapes) that could be used by 
interested scientists to test and compare different algorithmic alternatives. Beside 
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the drug combinations and the biological outputs, the datasets should also 
contain omic profiles (as genomics, microarray, proteomics and metabolomics) to 
specify the state of the model variables, at least for the individual drugs and for 
the main maxima in the landscape.  
Fundamental experimental and theoretical understanding of the 
morphology of the control landscape will assist in developing improved 
algorithms to direct combinatorial therapeutic search in favorable directions.  In 
hard computational problems it is well known that as the degree of constraint 
increases, there is a phase transition from problems where it is relatively easy to 
find satisfying solutions to a phase where it is difficult to find good solutions.  This 
phase transition has been studied intensively in model complex systems such as 
random K-SAT [77], however the implications for combinatorial drug discovery 
remain to be explored.  
Such new datasets may spur cross-fertilization from other quantitative 
sciences and new developments in computational biology, in the same way that 
large-scale genomic and proteomic datasets have already done [78]. 
 
 
8. CONCLUSIONS 
A systematic approach to the field of combinatorial drug interventions has 
only recently started and it is too early to have a complete picture of all 
differences versus combinatorial optimization in material sciences or engineering. 
There are, however, a few aspects we would like to point out.  
When explicit models are used in non-biological optimization efforts, there 
is usually just one type of model used in a particular application. Calzolari et. al., 
however, showed (Figure 10 of [44]) separate models of metabolism and of 
signal transduction as possible sources of inputs for the search. It would not be 
easy to unify them, even if the outputs can be combined. Other relevant classes 
of biological models with distinctive features do exist, for example 
electrophysiology models. Including different heterogeneous models might be 
especially necessary in the optimization of drug combinations because of the 
partial coverage of these models and because of the complexity of biological 
systems. 
Another feature to be noted is that the relation between drug and target is 
not simple; even targeted therapies have some off-target effects and we do not 
have a drug for every protein. It is therefore not possible to tune selectively all the 
parameters of a biological model as it might be done in many engineering 
applications. 
Finally we must consider that variation is an essential part of natural 
selection and therefore of any population of living organisms. In other words 
individual organisms of the same kind are necessarily more variable than 
machines or materials and cannot be represented equally well by generic explicit 
models. We might therefore expect hybrid approaches, which include biological 
search algorithms in addition to models, to play a larger role in the 
pharmacological control of living systems. 
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